← Back to Search

Active 1000 mg Tempol Solution for Mucositis

Phase 2
Waitlist Available
Research Sponsored by Matrix Biomed, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 weeks
Awards & highlights

Study Summary

This trial will assess whether Tempol can help prevent or reduce toxicities from cisplatin and radiation treatment in head and neck cancer patients. Mucositis, nephrotoxicity, and ototoxicity will be monitored over 10 weeks.

Eligible Conditions
  • Mucositis
  • Ototoxicity
  • Kidney Damage
  • Hearing Loss

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Mucositis
Nephrotoxicity

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active 1000 mg Tempol SolutionActive Control1 Intervention
Patients will take 1000 mg of Tempol a day for the duration of radiation treatment (6-8 weeks)
Group II: Placebo SolutionPlacebo Group1 Intervention
Patients will take placebo solution everyday for the duration of radiation treatment (6-8 weeks)

Find a Location

Who is running the clinical trial?

Matrix Biomed, Inc.Lead Sponsor
5 Previous Clinical Trials
130 Total Patients Enrolled
Benji CraneStudy DirectorMatrix Biomed, Inc.
~20 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top